Latest Non Dilutive Funding News

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

European Metals Holdings has secured a crucial funding pathway to complete the Definitive Feasibility Study for its Cinovec Lithium Project, combining a A$3 million placement with non-dilutive refinancing options to meet its €5.39 million share of a €11 million cash call.

Nova Minerals has garnered strong support from Alaska’s Governor and the Australian Consular-General for its Estelle Gold and Critical Minerals Project, aligning with key infrastructure and national security priorities.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Thor Energy has completed the sale of a 75% stake in its US uranium and vanadium projects to Metals One PLC, receiving £1 million in shares and a cash exclusivity payment. This deal allows Thor to focus on its hydrogen and helium ambitions while Metals One takes operational control.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

Iondrive Limited has won a $3.9 million government grant to advance its innovative urban mining technology, accelerating the construction of a pilot plant focused on critical minerals recovery from lithium-ion batteries.

SRJ Technologies clarifies its financial position and strategic rationale behind a recent capital raise and acquisition of a UAE entity, addressing ASX concerns over its viability and voluntary suspension.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.